LLY
resolvedEli Lilly and Company
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Eli Lilly's post-earnings gap-up reflects Wall Street's growing conviction that the GLP-1 franchise (Mounjaro/Zepbound) is entering a hyper-growth phase that fundamentally resets the company's earnings trajectory. The obesity and diabetes TAM is being continually revised upward — currently estimated at $100B+ by 2030 — and Lilly is capturing disproportionate share against Novo Nordisk with a superior efficacy profile. A 5.2% gap on 2.1x volume signals institutional accumulation, not just short covering, suggesting portfolio managers are repositioning ahead of what they see as a multi-year compounding story. The rerating thesis extends beyond GLP-1s alone. Lilly's pipeline depth — including donanemab for Alzheimer's (Kisunla, now FDA-approved), oral GLP-1 candidates (orforglipron), and next-generation weight-loss therapies (retatrutide) — represents a rare triple-engine growth profile in pharma. The market is likely pricing in not just beat-and-raise dynamics but a structural re-rating where LLY deserves a premium multiple (40-50x forward earnings) typically reserved for secular tech winners, not traditional pharma names. Key to sustaining this is manufacturing scale-up; any evidence that supply constraints are easing would be a major catalyst for further upside.
Analyzed by rerate-v2+glm-5.2 · Aug 6, 2026
Catalysts
- Zepbound/Mounjaro weekly scripts accelerating and supply constraints easing as new manufacturing capacity comes online
- Oral GLP-1 (orforglipron) Phase 3 data could expand TAM by removing injection barrier
- Kisunla (donanemab) commercial launch contributing incremental revenue in Alzheimer's — a massive underpenetrated market
- Potential next-gen obesity drug retatrutide showing superior weight loss profiles in trials
- International expansion of obesity franchise into EU and Japan markets
- Guidance raise reflecting stronger-than-expected demand elasticity and pricing power
Risks
- GLP-1 competition intensifying — Novo Nordisk next-gen candidates, plus Pfizer and Amgen pipeline threats
- Political and payer pressure on drug pricing, particularly for elective weight-loss use vs. diabetes
- Manufacturing/quality control stumbles at new production facilities could delay supply ramp
- Valuation compression risk — at ~45x+ forward earnings, any deceleration in script growth triggers sharp derating
- Patent cliff concerns on legacy franchises (Trulicity, Jardiance) as GLP-1 cannibalization accelerates
- Potential safety signals emerging from broader real-world GLP-1 use at scale
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $1185.71 | $1196.80 | $1161.20 | 2.90M |
| 📍 Day 2 | $1231.94 | $1231.94 | $1184.41 | 3.01M |
| Day 3 | $1214.70 | $1238.00 | $1209.53 | 1.55M |
| Day 4 | Pending | |||
| Day 5 | Pending | |||
Signal Breakdown
Gap held — only 0% erased, price maintained gains
Moderate volume decline (46%)
Higher highs with peak close on day 2 — continued buying interest
Minimal drawdown (0.7%) — price held firm
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026